GLP-1 Receptor Agonists for Diabetes: Evidence and Outcomes

View Evidence Brief

Evidence on outcomes studied for GLP-1 Receptor Agonists

Evidence related to GLP-1 receptor agonist therapies in diabetes studies.

Build your Evidence Workspace

Save evidence about the topics you care about.

Studies

100

Evidence Pairs

Strong Evidence

Evidence Strength: 70/100

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

GLP-1 Receptor Agonists evidence appears to center on HbA1c.

Among 82 indexed studies and 5 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 19 evidence pairs - 51 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTs

HbA1c

42 studies

EvidenceScore™

88/100

ConsistencyScore™

90/100

Body weight

38 studies

EvidenceScore™

86/100

ConsistencyScore™

91/100

Evidence Snapshot

Studies

Interventions

Outcomes

Strong evidence signals

Mixed evidence areas

Key Findings

Key patterns and insights identified across the research landscape

Strong positive signal

HbA1c

Across 16 studies, Semaglutide shows a consistent strong positive signal for HbA1c.

16 studies

EvidenceScore™: 88.16826923076923/100

View supporting studies

Moderate positive signal

Body weight

Across 13 studies, Semaglutide shows a consistent moderate positive signal for Body weight.

13 studies

EvidenceScore™: 85.77514792899409/100

View supporting studies

Moderate positive signal

BMI

Across 5 studies, Semaglutide shows a consistent moderate positive signal for BMI.

5 studies

EvidenceScore™: 84.95384615384616/100

View supporting studies

Moderate positive signal

HbA1c

Across 7 studies, Liraglutide shows a consistent moderate positive signal for HbA1c.

7 studies

EvidenceScore™: 84/100

View supporting studies

Strong positive signal

HbA1c

Across 5 studies, Dulaglutide shows a consistent strong positive signal for HbA1c.

5 studies

EvidenceScore™: 83.50769230769231/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

HbA1c is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

HbA1c

Body weight

HbA1c

42 studies

EvidenceScore™

88/100

ConsistencyScore™

90/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present

Evidence basis: 21 evidence pairs - 54 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

LDL cholesterol may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

LDL cholesterol

Total cholesterol

LDL cholesterol

3 studies

EvidenceScore™

79/100

ConsistencyScore™

63/100

Why this appears here

Positive effect signalLimited study volume

Evidence basis: 5 evidence pairs - 12 studies

View supporting studies

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Questions Answered by the Evidence

What outcomes has GLP-1 Receptor Agonists been studied for?

HbA1c, Body weight, and BMI are among the most studied areas in relation to GLP-1 Receptor Agonists.

Strong Evidence · Results are consistent across studies. · 82 studies · 76 RCTs

The evidence includes both beneficial and harmful or worsening results.

View top evidence signals ↓

HbA1c · Strong · 42 studies
Body weight · Strong · 38 studies
BMI · Strong · 15 studies

Do GLP-1 Receptor Agonists lower HbA1c?

GLP-1 Receptor Agonists appear to lower HbA1c.

Strong Evidence · Results are consistent across studies. · 42 studies · 42 RCTs

View top evidence signals ↓

HbA1c · Strong · 42 studies

Do GLP-1 Receptor Agonists affect body weight?

GLP-1 Receptor Agonists may affect body weight.

Strong Evidence · Results are consistent across studies. · 38 studies · 37 RCTs

View top evidence signals ↓

Body weight · Strong · 38 studies

Which outcomes have the strongest evidence for GLP-1 Receptor Agonists?

HbA1c, Body weight, and BMI have the strongest available evidence signals for GLP-1 Receptor Agonists.

Strong Evidence · Results are consistent across studies. · 60 studies · 59 RCTs

View top evidence signals ↓

HbA1c · Strong · 42 studies
Body weight · Strong · 38 studies
BMI · Strong · 15 studies

Where does GLP-1 Receptor Agonists need more research?

Proportion achieving HbA1c <7.0%, Blood glucose, and Mean amplitude of glycemic excursions (MAGE) need more research in relation to GLP-1 Receptor Agonists.

Moderate Evidence · Results are consistent across studies. · 9 studies · 9 RCTs

View top evidence signals ↓

Basal insulin dose · Moderate · 2 studies
Blood glucose · Moderate · 2 studies
Mean amplitude of glycemic excursions (MAGE) · Moderate · 2 studies

Browse all questions about GLP-1 Receptor Agonists

Overall Evidence Signals

Among 82 indexed studies and 5 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.